Antibody engineering is revolutionizing immuno-oncology, allowing for the synthesis of synthetic immunity by optimizing various components of antibody structure. Monoclonal antibodies (mAbs) and bispecific antibodies (BsAbs) with enhanced antibody effector functions haveRead More…
Bispecific antibodies, with two binding sites directed at two different antigens or two different epitopes on the same antigen, have shown some superiority in clinical therapeutic effects when compared with monoclonal antibodies,Read More…
With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With more clinical candidates and commercial success than everRead More…
Antibody fragmentation and/or disulfide bond (DSB) reduction are common phenomena in antibody production processes, mainly caused by non-enzymatic (environmental) factors and enzymatic catalysis. Compared with traditional monoclonal antibodies (mAbs), bispecific antibodies (bsAbs)Read More…
Distinctive BsAb Platform The problem of chain mismatches will reduce the yield of the bsAb, increase the difficulty of purification, and increase the production cost. Therefore, obtaining a correctly assembled bsAb hasRead More…
In the past two decades, advances in biotechnology have brought improvements in protein engineering and manufacturing technology, and promoted the development of increasingly complex bispecific antibodies (BsAbs). At present, more than 100Read More…
Nowadays, in the tide of research and development of biological agents, antibody drugs are in an explosive period. The major monoclonal antibody (McAb) drugs have accounted for more than half of theRead More…
In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by the U.S. Food and Drug Administration (FDA), becoming the first targeted therapy for patients with neurotrophic receptor tyrosine kinase (NTRK)Read More…
Blinatumomab is a CD19/CD3 bispecific antibody that is the first bispecific T cell engager (BiTE) and the first CD19-specific antibody approved by the U.S. Food and Drug Administration (FDA). As an immunotherapyRead More…